Effect of Blocking the Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) in a Rat Small Intestinal Transplantation Model.

阻断粘膜寻址细胞粘附分子-1 (MAdCAM-1) 在大鼠小肠移植模型中的作用。

基本信息

  • 批准号:
    16591784
  • 负责人:
  • 金额:
    $ 2.11万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2004
  • 资助国家:
    日本
  • 起止时间:
    2004 至 2005
  • 项目状态:
    已结题

项目摘要

[Puupose] The effect of blocking the expression of the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in a graft by an antibody, and immunohistochemical changes in the graft were monitored, using a rat small intestinal transplantation model.[Materials and Methods] Dark Agouti (DA) rat small intestines were heterotopically transplanted into Lewis (LEW) rats. The graft was treated with or without anti-MAdCAM-1 antibody, F(ab)2, during the operation. The survival of the grafts and histological changes, such as lymphocyte infiltration and destruction of the intestinal architecture in the epithelium villus thickess, villus height and submucosal thickness of the graft were examined. The expression of MAdCAM-1 and β7 integrin in the graft was also checked by immunostaining. Furthermore, graft infiltration lymphocytes, in mesenteric lymph nodes (MLN) and Peyer's patches (PP) were measured by FACS analysis.[Results] Survival was prolonged in the DA graft with anti MAdCAM-1 F(ab')2 treatment; DA to LEW: 7.0 ± 3.3 days, DA to LEW with the antibody: 24.6 ± 8.4 days (p< 0.05). Histological findings and scoring of the grafts were consistent with this result. Moreover, MAdCAM-1 expression itself was suppressed in grafts of the antibody-treated group. While a FACS analysis showed no difference in the % of CD4+ T cells and CD8+ T cells in the PP of the graft, CD4+ T cells in the MLN of the antibody treated graft were significantly low.[Conclusion] A strategy directed at blocking the adhesion molecule, MAdCAM-1, in the small intestinal grafts could be useful in prevention of acute rejection after small intestinal transplantation..
【目的】采用大鼠小肠移植模型,观察抗体阻断移植物粘膜寻址蛋白细胞粘附分子-1 (muc粘膜寻址蛋白细胞粘附分子-1,MAdCAM-1)表达的效果,以及移植物的免疫组织化学变化。【材料与方法】将DA大鼠小肠异位移植到Lewis大鼠体内。在手术过程中,移植物分别使用或不使用抗madcam -1抗体F(ab)2。观察移植物的存活情况和组织学变化,如淋巴细胞浸润和肠结构的破坏,观察移植物的上皮绒毛厚度、绒毛高度和粘膜下厚度。免疫染色法检测移植物中MAdCAM-1和β7整合素的表达。采用FACS法检测移植物浸润淋巴细胞、肠系膜淋巴结(MLN)和Peyer’s patches (PP)。[结果]抗MAdCAM-1 F(ab')2治疗可延长DA移植物的生存期;DA到LEW: 7.0±3.3天,DA到LEW带抗体:24.6±8.4天(p< 0.05)。移植物的组织学表现和评分与这一结果一致。此外,MAdCAM-1本身的表达在抗体处理组的移植物中被抑制。虽然FACS分析显示移植物PP中CD4+ T细胞和CD8+ T细胞的百分比没有差异,但抗体处理的移植物MLN中CD4+ T细胞的百分比明显低。[结论]阻断小肠移植物黏附分子MAdCAM-1的策略可能有助于预防小肠移植后的急性排斥反应。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of blocking the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in a rat small intestinal transplantation model.
阻断粘膜地址素细胞粘附分子-1 (MAdCAM-1) 在大鼠小肠移植模型中的作用。
  • DOI:
    10.1016/j.trim.2007.01.011
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    1.5
  • 作者:
    Y. Ihara;S. Miyagawa;T. Hasegawa;Takuya Kimura;Hengjie Xu;M. Fukuzawa
  • 通讯作者:
    M. Fukuzawa
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HASEGAWA Toshimichi其他文献

HASEGAWA Toshimichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
  • 批准号:
    10752046
  • 财政年份:
    2024
  • 资助金额:
    $ 2.11万
  • 项目类别:
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
  • 批准号:
    10751872
  • 财政年份:
    2024
  • 资助金额:
    $ 2.11万
  • 项目类别:
Crosstalk between purinergic signaling and the complement system in sepsis-induced immunosuppression.
脓毒症引起的免疫抑制中嘌呤能信号传导与补体系统之间的串扰。
  • 批准号:
    23H03013
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Graft localized drug delivery to augment beta cell replacement therapies for diabetes
移植局部药物递送以增强糖尿病的β细胞替代疗法
  • 批准号:
    480374
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
    Operating Grants
Regulation of prostate organogenesis by tissue-resident macrophages
组织驻留巨噬细胞对前列腺器官发生的调节
  • 批准号:
    10555589
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer
改造 T 细胞以克服抑制性受体信号,这些信号限制了过继性细胞疗法对卵巢癌的疗效
  • 批准号:
    10526155
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Epigenetically regulated stemness program and stem cell niche as targets in pediatric DIPG
表观遗传调控的干细胞程序和干细胞生态位作为儿科 DIPG 的目标
  • 批准号:
    10635435
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation
靶向 CCR6-CCL20 通路治疗银屑病关节和附着点炎症
  • 批准号:
    10699251
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 2.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了